Pillstats
Rx only · Solution · Intra-Arterial

Methotrexate

Methotrexate

1 ACTIVE SUPPLIER — US
openFDA · updated weekly
US4 NDCs
1 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
ATCL01BA01
RxCUI (US)6851
US makers1 labelers
Packages4
DEA / ScheduleNone

US acquisition costNADAC · per unit

Average across 1 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.

$0.380$0.761$1.14$1.52Dec 2025Apr 2026Jul 2026
$1.248
Latest avg · Jul 22, 2026
-6%
Since Dec 17, 2025
1
Active US suppliers
100%
Top-2 supplier share*

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

1.8K3.6K5.4K7.2K2025 Q12025 Q22025 Q32025 Q42026 Q1
5.2K
Rx · 2026 Q1
35K
Units dispensed
-13%
Rx vs. year ago
5
Quarters · since 2025 Q1

Who makes it1 active · 0 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

LabelerTypePackagesStatus
Hikma Pharmaceuticals USA Inc.unknown4SUPPLYING

Regulatory & supply eventsFDA · US

Shortages, recalls, and registration changes attached to this drug concept.

  • Mar 13, 2023
    SHORTAGEDrug shortage: Methotrexate Sodium Injection (Hikma Pharmaceuticals USA, Inc.)

    Methotrexate Sodium Injection — reported in shortage by Hikma Pharmaceuticals USA, Inc.. Therapeutic category: Oncology, Rheumatology.